| scholarly article | Q13442814 |
| P50 | author | Roy W. Beck | Q88156417 |
| Diabetic Retinopathy Clinical Research Network | Q98806904 | ||
| Adam R Glassman | Q98807054 | ||
| Lee M. Jampol | Q111076721 | ||
| Neil M. Bressler | Q112187433 | ||
| P2093 | author name string | Michele Melia | |
| Raj K Maturi | |||
| Danni Liu | |||
| Hani Salehi-Had | |||
| Omar S Punjabi | |||
| Jennifer K Sun | |||
| Abdhish R Bhavsar | |||
| P2860 | cites work | Angiostatic steroids. Method of discovery and mechanism of action | Q24550539 |
| World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects | Q28300546 | ||
| A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema | Q33355710 | ||
| Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema | Q33567438 | ||
| The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. | Q33860909 | ||
| Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. | Q33860915 | ||
| Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. | Q34157994 | ||
| Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab | Q34410772 | ||
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema | Q35575496 | ||
| Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment | Q35889168 | ||
| INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. | Q35922054 | ||
| Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema | Q39072730 | ||
| Angiogenesis: an update | Q40398731 | ||
| Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. | Q45133527 | ||
| PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA. | Q53614131 | ||
| Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells | Q74446280 | ||
| A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH | Q87031342 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dexamethasone | Q422252 |
| diabetic macular edema | Q18558081 | ||
| phase II clinical trial | Q42824440 | ||
| P577 | publication date | 2017-11-11 | |
| P1433 | published in | JAMA Ophthalmology | Q4787301 |
| P1476 | title | Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial |
| Q94461905 | A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study) |
| Q99238749 | Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review |
| Q54115470 | Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. |
| Q52611598 | Corneal Vibrations during Intraocular Pressure Measurement with an Air-Puff Method. |
| Q92671027 | Corticosteroids for Diabetic Macular Edema |
| Q52615212 | Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. |
| Q60913080 | Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies |
| Q90056412 | Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema |
| Q92696069 | Dexamethasone implant in the management of diabetic macular edema from clinician's perspective |
| Q59797366 | Diabetic macular edema: Evidence-based management |
| Q96172012 | Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group |
| Q96172050 | Editorial on the consensus statement on diabetic retinopathy care pathway |
| Q93184605 | Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial |
| Q90046873 | Emerging Insights and Interventions for Diabetic Retinopathy |
| Q89250688 | Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema |
| Q90158793 | Glucocorticoid-transactivated TSC22D3 attenuates hypoxia- and diabetes-induced Müller glial galectin-1 expression via HIF-1α destabilization |
| Q94600699 | Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol |
| Q50215366 | Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial |
| Q92003416 | Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data |
| Q90409273 | The Evolving Treatment of Diabetic Retinopathy |
| Q90197758 | The impact of artificial intelligence in the diagnosis and management of glaucoma |
| Q92025135 | The role of steroids in treating diabetic macular oedema in the era of anti-VEGF |
| Q96305369 | Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema |
Search more.